Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Mayo Clinic
Tianjin Medical University Second Hospital
Nagoya University
Emory University
University of Chicago
Astellas Pharma Inc
National Cancer Institute (NCI)
Mayo Clinic
pharmaand GmbH
Mayo Clinic
Wake Forest University Health Sciences
University Health Network, Toronto
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Karolinska University Hospital
Eli Lilly and Company
Cardiff University
Mansoura University
Dendreon
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Asan Medical Center
AstraZeneca
Bristol-Myers Squibb
Achieve Life Sciences